Prognostic Association of Liposomal Amphotericin B Doses Above 5 mg/kg/d in Mucormycosis: A Nationwide Epidemiologic and Treatment Analysis in Japan.

Masato TashiroHotaka NamieYuya ItoTakahiro TakazonoHiroshi KakeyaYoshitsugu MiyazakiHiroshi MukaeHiroshige MikamoFukuda TomooKazutoshi ShibuyaKoichi Izumikawa

Published in: Open forum infectious diseases (2023)

This study provides important insights into the precise epidemiology and treatment practices of mucormycosis. Treatment with liposomal amphotericin B at doses higher than 5 mg/kg/d did not improve outcomes relative to 5 mg/kg/d.

Keyphrases

healthcare
primary care
risk factors
metabolic syndrome
adipose tissue
skeletal muscle
weight loss
glycemic control